Antiplatelet agents (APA) and anticoagulants

WHAT IS RECOMMENDED

• Discuss the risks and benefits with the centre of reference or expertise responsible for the patient.
• Adapt the treatment to the patient’s clinical condition (epistaxis, gastrointestinal bleeding).
• After an ischemic stroke secondary to pulmonary arteriovenous malformations, there is no indication to continue this type of treatment (APA or anticoagulant) if all pulmonary arteriovenous malformations have been treated satisfactorily.

WHAT YOU SHOULD NOT DO

• Prescribe APAs or anticoagulants without having weighed the risks and benefits.